Compare Natera Inc. Common Stock (NTRA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Twist Bioscience Corp — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Twist Bioscience Corp trades at $143.94 (market cap $9.82B). The key difference: Natera Inc. Common Stock is far larger — about 5.8× Twist Bioscience Corp's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| NTRA | TWST | |
|---|---|---|
Market Cap | $57.03B | $9.82B |
Volume | 1,131,157 | 2,115,226 |
Sector | Health | Health |
52-Week High | $425.64 | $205.00 |
52-Week Low | $179.42 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $56.18B | $9.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Twist Bioscience (TWST) trades at $151.33, down 0.35% on the day, with a bullish technical signal but negative profitability. Revenue growth is strong, increasing from $204M in 2022 to $377M in 2025, yet net losses persist. Recent news highlights a partnership with Eli Lilly's TuneLab AI platform, boosting investor optimism. The stock is near its consensus price target of $153.70, with institutional buying noted in Q2 2026.
Outlook remains speculative; growth prospects from AI-driven drug discovery are promising, but profitability challenges and cash burn pose significant risks. Analyst consensus is bullish (73% buy ratings), yet high valuation multiples and consistent earnings misses warrant caution for investors seeking near-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
